271 related articles for article (PubMed ID: 28489307)
1. Non-alcoholic fatty liver and advanced fibrosis in the elderly: Results from a community-based Polish survey.
Hartleb M; Barański K; Zejda J; Chudek J; Więcek A
Liver Int; 2017 Nov; 37(11):1706-1714. PubMed ID: 28489307
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
Önnerhag K; Hartman H; Nilsson PM; Lindgren S
Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
[No Abstract] [Full Text] [Related]
4. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA.
Wijarnpreecha K; Thongprayoon C; Scribani M; Ungprasert P; Cheungpasitporn W
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):404-410. PubMed ID: 29215435
[TBL] [Abstract][Full Text] [Related]
5. Growth differentiation factor 15 predicts advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease.
Koo BK; Um SH; Seo DS; Joo SK; Bae JM; Park JH; Chang MS; Kim JH; Lee J; Jeong WI; Kim W
Liver Int; 2018 Apr; 38(4):695-705. PubMed ID: 28898507
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
Le MH; Devaki P; Ha NB; Jun DW; Te HS; Cheung RC; Nguyen MH
PLoS One; 2017; 12(3):e0173499. PubMed ID: 28346543
[TBL] [Abstract][Full Text] [Related]
7. Prescription of statins in suspected non-alcoholic fatty liver disease and high cardiovascular risk, a population-based study.
van den Berg EH; Wolters AAB; Dullaart RPF; Moshage H; Zurakowski D; de Meijer VE; Blokzijl H
Liver Int; 2019 Jul; 39(7):1343-1354. PubMed ID: 30968536
[TBL] [Abstract][Full Text] [Related]
8. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications.
Ciardullo S; Muraca E; Perra S; Bianconi E; Zerbini F; Oltolini A; Cannistraci R; Parmeggiani P; Manzoni G; Gastaldelli A; Lattuada G; Perseghin G
BMJ Open Diabetes Res Care; 2020 Feb; 8(1):. PubMed ID: 32049637
[TBL] [Abstract][Full Text] [Related]
9. The utility of noninvasive scores in assessing the prevalence of nonalcoholic fatty liver disease and advanced fibrosis in type 1 diabetic patients.
Singh A; Le P; Lopez R; Alkhouri N
Hepatol Int; 2018 Jan; 12(1):37-43. PubMed ID: 29318450
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and risk factors for non-alcoholic fatty liver in children and youth with obesity.
Jimenez-Rivera C; Hadjiyannakis S; Davila J; Hurteau J; Aglipay M; Barrowman N; Adamo KB
BMC Pediatr; 2017 Apr; 17(1):113. PubMed ID: 28446162
[TBL] [Abstract][Full Text] [Related]
11. The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999-2004.
Li L; Huang Q; Yang L; Zhang R; Gao L; Han X; Ji L; Zou X
Nutrients; 2022 Mar; 14(6):. PubMed ID: 35334881
[TBL] [Abstract][Full Text] [Related]
12. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.
Wong RJ; Liu B; Bhuket T
Aliment Pharmacol Ther; 2017 Nov; 46(10):974-980. PubMed ID: 28914448
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and risk factors for biopsy-proven non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in a prospective cohort of adult patients with gallstones.
García-Monzón C; Vargas-Castrillón J; Porrero JL; Alonso MT; Bonachía O; Castillo MJ; Marcos A; Quirós E; Ramos B; Sánchez-Cabezudo C; Villar S; Sáez A; Rodríguez de Cía J; del Pozo E; Vega-Piris L; Soto-Fernández S; Lo Iacono O; Miquilena-Colina ME
Liver Int; 2015 Aug; 35(8):1983-91. PubMed ID: 25708133
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of undiagnosed liver cirrhosis and advanced fibrosis in type 2 diabetic patients.
Arab JP; Barrera F; Gallego C; Valderas JP; Uribe S; Tejos C; Serrano C; Serrano C; Huete Á; Liberona J; Labbé P; Quiroga T; Benítez C; Irarrázaval P; Riquelme A; Arrese M
Ann Hepatol; 2016; 15(5):721-8. PubMed ID: 27493111
[TBL] [Abstract][Full Text] [Related]
15. Cohort study of non-alcoholic fatty liver disease, NAFLD fibrosis score, and the risk of incident diabetes in a Korean population.
Chang Y; Jung HS; Yun KE; Cho J; Cho YK; Ryu S
Am J Gastroenterol; 2013 Dec; 108(12):1861-8. PubMed ID: 24100261
[TBL] [Abstract][Full Text] [Related]
16. Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease.
Hagström H; Nasr P; Ekstedt M; Kechagias S; Önnerhag K; Nilsson E; Rorsman F; Sheikhi R; Marschall HU; Hultcrantz R; Stål P
Scand J Gastroenterol; 2017 Feb; 52(2):159-165. PubMed ID: 27650916
[TBL] [Abstract][Full Text] [Related]
17. Predictors of advanced fibrosis in non-cirrhotic non-alcoholic fatty liver disease in Germany.
Labenz C; Huber Y; Kalliga E; Nagel M; Ruckes C; Straub BK; Galle PR; Wörns MA; Anstee QM; Schuppan D; Schattenberg JM
Aliment Pharmacol Ther; 2018 Nov; 48(10):1109-1116. PubMed ID: 30288767
[TBL] [Abstract][Full Text] [Related]
18. Depression is associated with non-alcoholic fatty liver disease among adults in the United States.
Kim D; Yoo ER; Li AA; Tighe SP; Cholankeril G; Harrison SA; Ahmed A
Aliment Pharmacol Ther; 2019 Sep; 50(5):590-598. PubMed ID: 31328300
[TBL] [Abstract][Full Text] [Related]
19. High NAFLD fibrosis score in non-alcoholic fatty liver disease as a predictor of carotid plaque development: a retrospective cohort study based on regular health check-up data in China.
Yu X; Chen C; Guo Y; Tong Y; Zhao Y; Wu L; Sun X; Wu X; Song Z
Ann Med; 2021 Dec; 53(1):1621-1631. PubMed ID: 34498502
[TBL] [Abstract][Full Text] [Related]
20. High prevalence of apolipoprotein B dyslipoproteinemias in non-alcoholic fatty liver disease: The lifelines cohort study.
Nass KJ; van den Berg EH; Faber KN; Schreuder TCMA; Blokzijl H; Dullaart RPF
Metabolism; 2017 Jul; 72():37-46. PubMed ID: 28641782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
